Dr Wilson joins from AbbVie where he was the company’s Global Leader for Antibody Drug Conjugates.
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
Dr Wilson joins from AbbVie where he was the company’s Global Leader for Antibody Drug Conjugates.
Tags
Related posts
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
